Patents by Inventor Cigall Kadoch

Cigall Kadoch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210388040
    Abstract: The present invention provides compositions and methods for treating cancers with canonical BAF (cBAF) complex perturbations (e.g. synovial sarcoma or malignant rhabdoid tumor) using an agent that inhibits the formation, activity, and/or stability of the ncBAF complex.
    Type: Application
    Filed: October 15, 2019
    Publication date: December 16, 2021
    Inventors: Cigall Kadoch, Brittany C. Michel, Andrew D'Avino
  • Patent number: 10976320
    Abstract: Methods for identifying and treating cancer patients likely to respond to topoisomerase inhibitors or likely to fail to respond to topoisomerase inhibitors are provided. The methods take advantage of the newly discovered role of BAF complexes in decatenation of DNA by topoisomerase IIa. Cancer cells are frequently at least partly defective in BAF complex activity. Such cells are targeted for therapy using certain topoisomerase IIa inhibitors according to the disclosed methods of treatment. Therapy of such cells using other topoisomerase inhibitors should be avoided.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: April 13, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Emily Carla Dykhuizen, Diana Clare Hargreaves, Cigall Kadoch, Gerald R. Crabtree
  • Patent number: 10752628
    Abstract: The present invention includes compound and methods that are useful in treating certain cancers, such as synovial sarcomas.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 25, 2020
    Assignees: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Cigall Kadoch, Enrique Garcia-Rivera, Micah Maetani, Stuart L. Schreiber
  • Publication number: 20200206344
    Abstract: The present invention is based, in part, on the novel discovery of the interaction between EWS-FLI1 and BAF complexes, and methods of modulating same to treat cancer, including Ewing Sarcoma.
    Type: Application
    Filed: August 20, 2018
    Publication date: July 2, 2020
    Inventors: Cigall Kadoch, Gabriel Sandoval, Miguel Rivera, Gaylor Boulay
  • Publication number: 20190269761
    Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.
    Type: Application
    Filed: August 28, 2018
    Publication date: September 5, 2019
    Inventors: Cigall Kadoch, Gerald R. Crabtree
  • Publication number: 20180327407
    Abstract: The present invention includes compound and methods that are useful in treating certain cancers, such as synovial sarcomas.
    Type: Application
    Filed: November 16, 2016
    Publication date: November 15, 2018
    Inventors: CIGALL KADOCH, ENRIQUE GARCIA-RIVERA, MICAH MAETANI, STUART L. SCHREIBER
  • Publication number: 20180328913
    Abstract: The present invention provides methods of screening for compounds that interfere with interaction between ERG. ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with interaction between ERG, ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins are also provided.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 15, 2018
    Inventors: Cigall Kadoch, Gabriel Sandoval, William C. Hahn
  • Publication number: 20180303802
    Abstract: Methods useful in the treatment of synovial sarcoma are provided. The methods comprise administering to a subject suffering from synovial sarcoma a compound as disclosed herein. Also provided are novel compounds having therapeutic effects on subjects suffering from synovial sarcoma and pharmaceutical compositions comprising the compounds. The compounds were identified by screening for agents that promote the assembly of wild-type BAF (also called mSWI/SNF) complexes in modified SS cells.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 25, 2018
    Inventors: Cigall KADOCH, Gerald R. CRABTREE
  • Publication number: 20180305424
    Abstract: Methods of inducibly targeting a chromatin effector to a genomic locus are provided. Aspects of the methods include employing a chemical inducer of proximity (CIP) system. Aspects of the invention further include methods of screening candidate agents that modulate chromatin-mediated transcription control and methods of inducibly modulating expression of a coding sequence from genomic locus. Also provided are compositions, e.g., cells, reagents and kits, etc., that find use in methods of the invention.
    Type: Application
    Filed: October 25, 2016
    Publication date: October 25, 2018
    Inventors: GERALD R. CRABTREE, Somon M.G. Braun, Joseph Paul Calarco, Cigall Kadoch
  • Patent number: 10105420
    Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: October 23, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Cigall Kadoch, Gerald R. Crabtree
  • Publication number: 20170014491
    Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.
    Type: Application
    Filed: July 20, 2016
    Publication date: January 19, 2017
    Inventors: Cigall Kadoch, Gerald R. Crabtree
  • Patent number: 9410943
    Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 9, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Cigall Kadoch, Gerald R. Crabtree
  • Publication number: 20150185221
    Abstract: Methods for identifying and treating cancer patients likely to respond to topoisomerase inhibitors or likely to fail to respond to topoisomerase inhibitors are provided. The methods take advantage of the newly discovered role of BAF complexes in decatenation of DNA by topoisomerase IIa. Cancer cells are frequently at least partly defective in BAF complex activity. Such cells are targeted for therapy using certain topoisomerase IIa inhibitors according to the disclosed methods of treatment. Therapy of such cells using other topoisomerase inhibitors should be avoided.
    Type: Application
    Filed: May 21, 2014
    Publication date: July 2, 2015
    Inventors: Emily Carla Dykhuizen, Diana Clare Hargreaves, Cigall Kadoch, Gerald R. Crabtree
  • Publication number: 20140288162
    Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Inventors: Cigall Kadoch, Gerald R. Crabtree